Eosinophilic esophagitis: Allergic contribution, testing, and management

被引:10
作者
Amindra A. Arora
Catherine R. Weiler
David A. Katzka
机构
[1] Department of Gastroenterology and Hepatology, Mayo Foundation, Rochester, MN 55905
[2] Department of Allergic Diseases, Mayo Foundation, Rochester, MN 55905
关键词
Allergy; Eosinophilic esophagitis; Esophagitis; Food antigens; Th2; pathway;
D O I
10.1007/s11894-012-0254-8
中图分类号
学科分类号
摘要
Both basic science and clinical data indicate a strong role for allergy as a cause of eosinophilic esophagitis. As a result, one of the desired goals of therapy is identification and elimination of food antigens that trigger the allergic inflammatory pathway. Traditional methods for identification of causative food antigens include induction of symptoms with exposure to the antigen, demonstration of serum IgE antibodies against antigens and induction of immediate (IgE) or delayed (Th2) reactions against dermal instillation of antigens. Although some data support the use of these tests in patients with eosinophilic esophagitis, they are limited in this disease. This limitation results from an inability to provoke recognizable symptoms and a lack of concordance between allergies identified in the skin and the blood with the antigens that trigger esophageal disease. As a result, allergy therapy in eosinophilic esophagitis consists of global elimination of food antigens with an elemental diet or exclusion of the most common antigens. As compliance is difficult with these strategies, the mainstay of allergy therapy in eosinophilic esophagitis has become the use of medications that blunt the allergic pathway such as steroids with a future aimed toward more specific inhibitors of this pathway in eosinophilic esophagitis specifically. © Springer Science+Business Media, LLC 2012.
引用
收藏
页码:206 / 215
页数:9
相关论文
共 64 条
[31]  
Blanchard C., Mingler M.K., Vicario M., Abonia J.P., Wu Y.Y., Lu T.X., Collins M.H., Putnam P.E., Wells S.I., Rothenberg M.E., IL-13 involvement in eosinophilic esophagitis: Transcriptome analysis and reversibility with glucocorticoids, Journal of Allergy and Clinical Immunology, 120, 6, pp. 1292-1300, (2007)
[32]  
Lucendo A.J., De Rezende L., Comas C., Caballero T., Bellon T., Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis, Am J Gastroenterol, 103, pp. 2184-2193, (2008)
[33]  
Whitney-Miller C.L., Katzka D., Furth E.E., Eosinophilic esophagitis: A retrospective review of esophageal biopsy specimens from 1992 to 2004 at an adult academic medical center, Am J Clin Pathol, 131, pp. 788-792, (2009)
[34]  
Shamssain M., Trends in the prevalence and severity of asthma, rhinitis and atopic eczema in 6- to 7- and 13- to 14-yr-old children from the north-east of England, Pediatric Allergy and Immunology, 18, 2, pp. 149-153, (2007)
[35]  
Stafford R.S., Ma J., Finkelstein S.N., Haver K., Cockburn I., National trends in asthma visits and asthma pharmacotherapy, 1978-2002, Journal of Allergy and Clinical Immunology, 111, 4, pp. 729-735, (2003)
[36]  
Branum A.M., Lukacs S.L., Food allergy among children in the United States, Pediatrics, 124, pp. 1549-1555, (2009)
[37]  
Gupta R., Sheikh A., Strachan D.P., Anderson H.R., Time trends in allergic disorders in the UK, Thorax, 62, 1, pp. 91-96, (2007)
[38]  
Rizo Pascual J.M., De La Hoz Caballer B., Redondo Verge C., Terrados Cepeda S., Roy Arino G., Riesco Lopez J.M., Camarero Salces C., Allergy assessment in childrenwith eosinophilic esophagitis, J Investig Allergol Clin Immunol, 21, pp. 59-65
[39]  
Arora A.S., Yamazaki K., Eosinophilic esophagitis: Asthma of the esophagus?, Clinical Gastroenterology and Hepatology, 2, 7, pp. 523-530, (2004)
[40]  
Rothenberg M.E., Mishra A., Collins M.H., Putnam P.E., Pathogenesis and clinical features of eosinophilic esophagitis, Journal of Allergy and Clinical Immunology, 108, 6, pp. 891-894, (2001)